Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new... see more

Recent & Breaking News (NDAQ:BLUE)

LAWSUIT FILED: bluebird bio, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton LLP

ACCESSWIRE IA February 12, 2021

bluebird bio to Separate Oncology Business into Independent Company

Business Wire January 11, 2021

Treatment with Investigational LentiGlobin(TM) Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Group C of Phase 1/2 HGB-206 Clinical Study Presented at 62nd Annual ASH Meeting

Business Wire December 7, 2020

Long-Term Data for bluebird bio's betibeglogene autotemcel (beti-cel) Gene Therapy Show Patients Across Ages and ?-thalassemia Genotypes Achieve Transfusion Independence and Remain Free from Transfusions Up to Six Years Presented at 62nd ASH Meeting

Business Wire December 5, 2020

Bristol Myers Squibb and bluebird bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, in Relapsed and Refractory Multiple Myeloma at ASH 2020

Business Wire December 5, 2020

Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta's MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease

Business Wire December 4, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of bluebird bio, Inc. - BLUE

GlobeNewswire November 30, 2020

bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

Business Wire November 24, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE

ACCESSWIRE IA November 18, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE

GlobeNewswire November 16, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE

ACCESSWIRE IA November 14, 2020

SHAREHOLDER ALERT: Investigation of bluebird Announced by Holzer & Holzer, LLC

Newsfile November 11, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE

PR Newswire November 10, 2020

bluebird bio Announces November Investor Events

Business Wire November 10, 2020

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of bluebird bio, Inc. (BLUE) Investigation

ACCESSWIRE IA November 9, 2020

bluebird bio to Present Data from Gene and Cell Therapy Programs During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

Business Wire November 5, 2020

bluebird bio Reports Third Quarter 2020 Financial Results and Highlights Operational Progress

Business Wire November 4, 2020

bluebird bio Announces European Medicines Agency's Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D(TM)) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)

Business Wire October 2, 2020

bluebird bio to Present at Jefferies Cell Therapy Virtual Summit

Business Wire September 28, 2020

bluebird bio's LentiGlobin(TM) for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency

Business Wire September 23, 2020